Articles On Imugene (ASX:IMU)

Highlights The Australian share market opened higher on Tuesday. The ASX 200 rose 10.40 points, or 0.15%, to 6,974.90 at the open. The index has gained 2.17% in the past five days. The Australian share market opened hi...

Clinical trials access startup HealthMatch has raised $10 million in Series C. The round was led by the company’s original backer, Folklore Ventures. Paul Bassat’s Square Peg Capital led an $18 million Series B in the Sydney-based startup i...

Imugene (IMU) enters a trading halt ahead of a capital raise to facilitate investment from two new institutional investorsTrading of IMU shares will be paused until Wednesday, September 14, by which time the company should have released fur...

ASX 200 gains 1%  Small Caps index does the same, but then gives it all back ODE wins and NIC MD Justin Werner: Hengjaya joins world’s best nickel resources   The ASX Emerging Companies index (XEC) has given all away its early gains on Mo...

The Imugene Limited (ASX: IMU) share price isn’t going anywhere right now. The stock has been put into a trading halt earlier this morning pending the announcement of a capital raising. The Imugene share price last traded at 22.5 cents....

Highlights The ASX 200 benchmark index closed up today (September 9), gaining 0.66% to 6,894.20 points. Over the last five days, the index has gained 0.96%, but is down 7.39% for the last year to date. Materials was the best performin...

ShareCafeLunch Report: 9 September, 2022 by Paul Sanger   Australian shares are on track to end the week higher after Wall Street made gains overnight. The ASX held a minute’s silence at 11am to mark the death of Queen Elizabeth II. At noon...

The Lithium Power International Ltd (ASX: LPI) share price is immobile today following the ASX’s decision to grant a company-requested trading pause. Before being placed on the back-burner, the Lithium Power share price has been enjoyin...

The Imugene Ltd (ASX: IMU) share price is trading well into the green in early afternoon trade on Thursday. At the time of writing, shares in the immuno-oncology company are swapping hands at 23 cents apiece, 4.55% higher on the day....

The ResApp Health Ltd (ASX: RAP) share price is in the green today as investors digest the latest news on Pfizer’s proposed takeover bid. Shares in the ASX healthcare company are up 0.98%, trading at 21 cents at the time of writing after s...

There’s a new development in the fight against the Zika virus. Invion (ASX:IVX) has just demonstrated that its Photosoft compounds were >99% effective in cell-based assays following the application of light. The study showed that Photoso...

Imugene (IMU) doses the first patient in its nextHERIZON phase two clinical trialThe trial is investigating its HER-Vaxx candidate when combined with other cancer treatments in patients with gastric cancerThe primary goal is to measure safe...

Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced that the first patient has been dosed in the nextHERIZON Phase 2 clinical trial.

Highlights The ASX 200 benchmark index closed up today (5 September), gaining 0.34% to end at 6,852.20 points. Over the last five days, the index has lost 1.63% and it has plunged 8.92% over the last 52 weeks. Energy was the best perf...

The ASX finishes higher on Monday Energy / Resource only outperforming sectors  ASX 200 quarterly rebalance sees 8 stocks in and 8 stocks out of the index The ASX ended Monday higher by 0.2% and trimmed last week’s losses despite a weak l...

The share market steadied on the eve of an increase in interest rates as a US market holiday and a rebound in key commodities encouraged buyers. The S&P/ASX 200 bounced 23.5 points or 0.34 per cent from Friday’s five-week low. Gai...

A rebound in resource stocks helped the share market weather weak overseas leads ahead of a likely rate rise tomorrow. The S&P/ASX 200 bounced nine points or 0.12 per cent from Friday’s five-week low.   Gains in the energy and mat...

ShareCafeLunch Report: 5 September, 2022 by Paul Sanger   The ASX moved higher in Monday trading, despite the weaker markets in the US on Friday. At noon, the S&P/ASX 200 is 0.28 per cent or 18.80 points higher at 6847.50. The SPI futur...

Biotechnology company Imugene (IMU) opens two additional cohorts for its phase one metastatic advanced solid tumours (MAST) studyThe company reports its first cohort for the intratumoral (IT) administration of its cancer-killing VAXINIA vir...

Pharmaxis gets ~$5m to collaborate on a Phase 2 study of lead drug, PXS‐4728. Imugene escalates to the next dosage in Phase 1 trial Leading charity, Parkinson’s UK, will provide £2.9m (~$5m) to fund a Phase 2 study of the Pharmaxis (ASX:P...

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. In this podcast, Motl...

The Imugene Limited (ASX: IMU) share price is in the red today despite a clinical trial update. Imugene shares are currently trading at 25.75 cents, a 0.96% fall. For perspective, the S&P/ASX 200 Health Care Index (ASX: XHJ) is slidi...

World Overnight SPI Overnight 6839.00 – 69.00 – 1.00% S&P ASX 200 6986.80 – 11.50 – 0.16% S&P500 3955.00 – 31.16 – 0.78% Nasdaq Comp 11816.20 – 66.93 – 0.56% DJIA 31510.43 – 280.44 – 0.88% S&P500 VIX 25.87 – 0.34 –...

ShareCafeEvening Report: 31 August, 2022 by Paul Sanger   Australian shares were weaker today, dragged down by mining and energy stocks on weak commodity prices. At the closing bell, the S&P/ASX 200 was 0.16 per cent or 11.50 points low...

The S&P/ASX 200 Index (ASX: XJO) put out a wobbly performance on Wednesday, opening and closing in the red despite gaining for much of the session. The index closed 0.16% lower at 6,986.80 points. Sadly, today marks the unofficial end...

The Imugene Limited (ASX: IMU) share price is on mute after the ASX-listed biotech company reported its results for FY22. After a wobbly start this morning, the Imugene share price has now stalled at yesterday’s closing price of 24 cents...

The S&P/ASX 200 Index (ASX: XJO) bounced back today following a 2% tumble that saw only four shares close higher on Monday. The index lifted 0.47% in Tuesday’s session to close at 6,998.30 points. In the lead was the S&P/ASX 200...

The ASX 200 bounced back on Tuesday Woodside triples dividends All 11 sectors finish in the green Local shares reclaimed some of Monday’s losses, finishing the day 0.65% higher. All 11 sectors finished in the green, led by by Tech and Ene...

The stock market suffered its heaviest loss in two and a half months as investors reacted to rates jitters on Wall Street and unexpectedly strong retail sales figures. The S&P/ASX 200 slumped 139 points or 1.95 per cent to 6965.5. Ju...

The share market slumped to a three-and-a-half-week low after interest rate jitters triggered Wall Street’s worst sell-off in two months. The S&P/ASX 200 dived 149 points or 2.09 per cent by the halfway mark. All 11 sectors declin...

ASX healthcare shares have been a mixed bag this earnings season, with some names completely blowing it out of the park, whereas others have left more to be desired. The S&P/ASX 200 Health Care index (ASX: XHJ) finished up 122 basis p...

The Appen Ltd (ASX: APX) share price took off in early trade on Thursday before tumbling into the red after the company posted its earnings for the first half. As The Motley Fool Australia reported earlier, the provider of data for machine...

The Appen Ltd (ASX: APX) share price is in focus after the machine learning and artificial intelligence data provider released its earnings for the first half. The Appen share price closed Wednesday’s session at $4.17. Appen share price...

The Imugene share price surged 20x to 71c before plunging to 25c in 2022 Here’s what the experts predict will happen to the Imugene share price in the next 12 months We discuss the opportunities and risks in Imugene’s pipeline Imugene (AS...

The BrainChip Holdings Ltd (ASX: BRN) share price is in the green in early trading on Wednesday amid the company posting its half-year financial report for FY22. Shares of the artificial intelligence tech company are currently trading 2.08...

The S&P/ASX 200 Index (ASX: XJO) shares in this article may not be thought of as leading ASX dividend shares. However, I believe that the companies I’m going to reveal should be counted as dividend beasts. Each of the names below hav...

With ASX reporting season in full swing, S&P/ASX 200 Index (ASX: XJO) shares are declaring dividends left, right, and centre. Once dividends are declared, there’s a cut-off date to determine which shareholders are entitled to the upc...

On Tuesday, the S&P/ASX 200 Index (ASX: XJO) was out of form again and sank into the red. The benchmark index fell 1.2% to 6,961.8 points. Will the market be able to bounce back from this on Wednesday? Here are five things to watch:...

The Imugene Limited (ASX: IMU) share price finished the session on Tuesday at 25 cents — down 3.85%. This is broadly in line with the general market, which also had a poor showing today. The S&P/ASX 200 Health Care Index (ASX: XHJ) fe...

The ASX 200 index fell by 1% on Tuesday Energy stocks rose as European’s benchmark for natural gas surged 20% overnight T. Rowe Price has downgraded Aussie stocks from overweight to neutral   Local shares finished lower by 1% for the seco...

The ASX 200 finished lower today Xero dragged down Tech sector  Australia’s jobless rate is at 3.4% lowest in almost half a century   The ASX 200 index fell for the first time this week, down by 0.30%, as Tech stocks dragged the bourse lo...

The ASX 200 is up by 0.20% on Wednesday Australia’s wage increases by only 2.6% Earnings results dominate newsflow   The ASX 200 notched up its third consecutive winning day after finishing slightly above water by 0.30% on Wednesday. Cons...

The market may have been pushing higher again on Tuesday, but the same cannot be said for the Appen Ltd (ASX: APX) share price. The artificial intelligence data services company’s shares continued their slide with a decline of almost 1%...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is plummeting after coming out of a trading halt this morning. At the time of writing, the biopharmaceutical company’s shares are fetching at $1.45, down 26.95%. What’s drivi...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX Powerplays. Several ASX health stocks have...

The ASX 200 rose by 1% on Thursday The lithium sector caught a bid on the back off a report from China Bitcoin has surged in the last 24 hours   Aussie shares rose by 1% today following the lower than expected US CPI data overnight that p...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is going nowhere today after the company requested a trading halt.  The Paradigm share price has rocketed from $1.05 per share on 28 July to $1.99 per share at Wednesday’s close...

Highlights The ASX 200 benchmark index ended in red today, losing 0.53% to end at 6,992.70 points. Over the last five days, the index is virtually unchanged, but is down 6.07% for the last year to date. Bottom performing stocks in thi...

Highlights The ASX 200 benchmark index ended in red today, losing 0.53% to end at 6,992.70 points. Over the last five days, the index is virtually unchanged, but is down 6.07% for the last year to date. Bottom performing stocks in thi...

The S&P/ASX 200 Index (ASX: XJO) slumped on Wednesday, weighed down by tech shares. The index was 0.53% lower at 6,992.70 points at the market’s close. A poor trade on Wall Street and rising bond yields might have weighed on the S&am...